Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens are the active components in combination vaccines (DTaP, Tdap) to prevent diphtheria (caused by *Corynebacterium diphtheriae*), tetanus (caused by *Clostridium tetani*), and pertussis (caused by *Bordetella pertussis*). The diphtheria and tetanus components are inactivated, detoxified toxins (“toxoids”), while the pertussis component consists of purified, important bacterial antigens (such as pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae) rather than whole bacterial cells. These antigens are not drug targets but are designed to elicit adaptive immunity, mostly antibody-mediated, to neutralize toxins and facilitate clearance of infection if exposure occurs[9][5][7].
Induction of protective immunity via adaptive immune response to toxins and/or bacterial virulence factors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphtheria toxoid, Tetanus toxoid, and Acellular pertussis antigens (DTaP (for children), Tdap (for adolescents/adults)[9][7]).